Status:
COMPLETED
Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).
Eligibility Criteria
Inclusion
- Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects, who require treatment with liraglutide
Exclusion
- Subjects who are or have previously been on liraglutide
- Subjects who have previously been enrolled in the study
- Subjects with a hypersensitivity to liraglutide or to any of the excipients
- Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the study periods
- Subjects with cancer (except basal cell skin cancer or squamous cell skin cancer) or any clinically significant disorder, except for conditions associated with type 2 diabetes mellitus history which in the physicians' opinion could interfere with the results of the trial
- Known or suspected abuse of alcohol or narcotics
Key Trial Info
Start Date :
July 19 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 28 2015
Estimated Enrollment :
4121 Patients enrolled
Trial Details
Trial ID
NCT01403025
Start Date
July 19 2011
End Date
December 28 2015
Last Update
February 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Tokyo, Japan, 1000005